The Center for Biosimilars recaps the top 5 stories in biosimilars news for the week of July 31, 2017.
Transcript
Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of July 31.
Number 5: A recent survey of Canadian patients highlights serious concerns about automatic substitution of biosimilars for reference products.
Number 4: Biosimilar developer Coherus has moved for a stay of discovery in its BPCIA litigation over pegfilgrastim, citing the company’s need to preserve its resources.
Number 3: The FDA Reauthorization Act of 2017 was passed by the Senate on Thursday. The must-pass bill reauthorizes user fees for biosimilar applicants.
Number 2: It was a busy week for trastuzumab biosimilars, with biologics license applications filed by Amgen and Allergan as well as Celltrion and Teva.
And Number 1: Brian Lehman takes a close look at the potential impact of Merck’s launch of Renflexis at a 35% discount off the list price of the reference, Remicade, in the US marketplace.
Finally, last week, our newsletter asked you to share your thoughts on how great a discount payers are expecting for biosimilar products. To view results of the poll, follow The Center for Biosimilars® on LinkedIn.
To sign up for our weekly newsletter or to read these articles and more, visit www.centerforbiosimilars.com.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Unifying Standards: The Need for Streamlined Biosimilar Development
October 22nd 2024At the 2024 GRx+Biosims conference, industry leaders and regulatory experts underscored the urgency of unifying global standards and simplifying the biosimilar development process, sharing insights on recent advancements and the necessity for greater collaboration between manufacturers and regulatory agencies.
Cost Savings and Efficacy of Biosimilars in Psoriasis Treatment for Veterans
October 17th 2024Biosimilars are safe, effective, and well-tolerated for psoriasis treatment, providing significant cost savings for the Veterans Health Administration, which saved over $67 million in 2023, while highlighting ongoing provider concerns regarding their use.